Immutep’s Promising Clinical Developments and Strategic Collaborations Earn a Buy Rating

In a report released on March 25, Jason McCarthy from Maxim Group maintained a Buy rating on Immutep (IMMP – Research Report), with a price target of $12.00.

Jason McCarthy has given his Buy rating due to a combination of factors surrounding Immutep’s promising clinical developments and strategic collaborations. The initiation of the Phase 3 TACTI-004 trial, which evaluates the combination of eftilagimod alpha with Keytruda and chemotherapy in first-line metastatic non-small cell lung cancer (NSCLC), is a significant milestone. This trial aims to challenge the current standards of care and has shown encouraging progression-free survival results in earlier studies.
Additionally, Immutep’s lead product candidate, eftilagimod alpha, has demonstrated favorable outcomes in the INSIGHT-003 study, with a median progression-free survival of 12.7 months and a median overall survival of 32.9 months. These results compare positively against existing treatments, highlighting the potential of Immutep’s approach. The company’s strategic partnerships with major pharmaceutical firms like Merck further bolster its prospects, contributing to McCarthy’s optimistic outlook and the Buy rating.